Celgene Announces Additional $3 Billion Share Repurchase Authorization
June 15 2016 - 6:30AM
Business Wire
Celgene Corporation (NASDAQ:CELG) today announced that during
its June meeting the Company's Board of Directors authorized the
repurchase of up to an additional $3.0 billion of the Company's
common stock.
This open-ended program is effective immediately. Purchases may
be made in the open market or in privately negotiated transactions
from time to time, as determined by Celgene's management and in
accordance with the requirements of the Securities and Exchange
Commission. Celgene now has a total of approximately $5.3 billion
available from previous authorizations plus the new authorization.
Since 2009, Celgene has returned approximately $15.2 billion to
shareholders through the repurchase program.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, FaceBook and
YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160615005244/en/
Celgene CorporationPatrick E. Flanigan III,
908-673-9969Corporate VP, Investor RelationsorBrian Gill,
908-673-9530VP, Corporate Communications
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024